Treatment Outcomes in Infections Caused by “SPICE” (Serratia, Pseudomonas, Indole-positive Proteus, Citrobacter, and Enterobacter) Organisms: Carbapenem versus Noncarbapenem Regimens

Clinical Therapeutics

Volumn 39, Issue 1, 2017, Pages 170-176

  Moy, Stanley ^a   Sharma, Roopali ^a,b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b TOURO COLLEGE   (United States)

Author keywords

AmpC lactamase; bacteremia; carbapenem; urinary tract infection

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BLOOD CULTURE; CATHETER INFECTION; CITROBACTER; CLINICAL OUTCOME; CLINICAL PRACTICE; COHORT ANALYSIS; CONCURRENT INFECTION; CONTROLLED STUDY; ENTEROBACTER; ENTEROBACTERIACEAE INFECTION; FEMALE; GRAM NEGATIVE SEPSIS; HOSPITAL MORTALITY; HUMAN; LENGTH OF STAY; MALE; MEDICAL RECORD REVIEW; NONHUMAN; PROTEUS; PSEUDOMONAS; RETROSPECTIVE STUDY; SERRATIA; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; URINARY TRACT INFECTION; URINE CULTURE; BACTEREMIA; COMPARATIVE STUDY; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; CITROBACTER; ENTEROBACTER; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROTEUS; PSEUDOMONAS; RETROSPECTIVE STUDIES; SERRATIA;

EID: 85009179744     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.11.025     Document Type: Article

References (14)

1. 1 Bush, K., Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant gram-negative infections. Crit Care, 14, 2010, 224.
2. 2 Patel, M.H., Trivedi, G.R., Patel, S.M., Vegad, M.M., Antibiotic susceptibility pattern in urinary isolates of gram negative bacilli with special reference to AmpC β-lactamase in a tertiary care hospital. Urol Ann 2 (2010), 7–11.
3. 3 Choi, S.H., Lee, J.E., Park, S.J., et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: Implications for antibiotic use. Antimicrob Agents Chemother 52 (2008), 995–1000.
4. 4 Jacoby, G.A., AmpC beta-lactamases. Clin Microbiol Rev 22 (2009), 161–182.
5. 5 Harris, P.N., Ferguson, J.K., Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: What are the alternatives to carbapenems, quinolones and aminoglycosides?. Int J Antimicrob Agents 40 (2012), 297–305.
6. 6 Delgado-Valverde, M., Sojo-Dorado, J., Pascual, A., Rodriguez-Bano, J., Clinical management of infections caused by multidrug-resistant Enterobacteriaceae. Ther Adv Infect Dis 1 (2013), 49–69.
7. 7 Le Gall, J.R., Lemeshow, S., Saulnier, F., A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270 (1993), 2957–2963.
8. 8 Siedner, M.J., Galar, A., Guzman-Suarez, B.B., et al. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis 58 (2014), 1554–1563.
9. 9 Tamma, P.D., Girdwood, S.C., Gopaul, R., et al. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae. Clin Infect Dis 57 (2013), 781–788.
10. 10 Sanders, W.E. Jr, Tenney, J.H., Kessler, R.E., Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 23 (1996), 454–461.
11. 11 Blanchette, L.M., Kuti, J.L., Nicolau, D.P., Nailor, M.D., Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae. Scand J Infect Dis 29 (2014), 1–6.
12. 12 Hilty, M., Sendi, P., Seiffert, S.N., et al. Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: Is cefepime adequate therapy?. Int J Antimicrob Agents 41 (2013), 236–249.
13. 13 Chaubey, V.P., Pitout, J.D., Dalton, B., et al. Clinical and microbiological characteristics of bloodstream infections due to AmpC β-lactamase producing Enterobacteriaceae: An active surveillance cohort in a large centralized Canadian region. BMC Infect Dis, 14, 2014, 647.
14. 14 Marcos, M., Inurrieta, A., Soriano, A., et al. Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia. J Antimicrob Chemother 62 (2008), 397–403.